| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6093732 | Gastroenterology | 2014 | 11 Pages |
Abstract
In patients with CD, the incidence of malignancy with adalimumab monotherapy was not greater than that of the general population. Co-administration of immunomodulator therapy and adalimumab was associated with an increased risk of NMSC and other cancers.
Keywords
CESAMENCIIBDSIRTNFRCTNMSCCDAIRandomized controlled trialSurveillance Epidemiology and End ResultsCrohn's diseaseInflammatory bowel diseasethiopurinenonmelanoma skin cancerSEERCrohn's Disease Activity IndexAnti-Tumor Necrosis Factorconfidence intervaltumor necrosis factorNational Cancer Institutestandardized incidence ratio
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Mark T. Osterman, William J. Sandborn, Jean-Frederic Colombel, Anne M. Robinson, Winnie Lau, Bidan Huang, Paul F. Pollack, Roopal B. Thakkar, James D. Lewis,